[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-traumatic-osteoarthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-traumatic-osteoarthritis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,49,77,106,138,161,188,212],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100504462","gait-rehabilitation-to-treat-fastoa-100504462",false,"NCT05848622","Gait Rehabilitation to Treat FastOA","Inclusion Criteria:\n\n* Have completed all other formal physical therapy\n* Are between the ages of 16 and 35\n* Underwent an anterior cruciate ligament reconstruction (ACLR) between 6 and 60 months prior to enrollment\n* Demonstrate underloading during gait (vGRF- impact peak \\\u003C1.12 x BW)\n\nExclusion Criteria:\n\n* A multiple ligament surgery (i.e., PCL)\n* A lower extremity fracture (i.e., displaced tibial plateau fracture)\n* Knee osteoarthritis","ALL","16 Years","35 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to determine the effects of real-time gait biofeedback delivered over a 6-week period on early markers of FastOA and conduct 6-week and 6-month follow-up assessments in anterior cruciate ligament reconstructed patients.",[26,27,28,29,30,31,32],"Anterior Cruciate Ligament Injuries","Post-traumatic Osteoarthritis","Knee Osteoarthritis","Osteo Arthritis Knee","Knee Injuries","Cartilage, Articular","Gait",[34,35],"Biofeedback","FastOA","RECRUITING","2026-06-24",{"date":39,"type":40},"2026-06-25","ACTUAL",{"date":42,"type":40},"2023-06-13",{"date":44,"type":20},"2027-06",{"name":46,"class":47},"University of North Carolina, Chapel Hill","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":75,"locationsCount":48},"100406426","early-phase-1-montelukast-as-a-potential-chondroprotective-treatment-following-anterior-cruciate-ligament-reconstruction-mocha-trial-100406426","NCT04572256","MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)","MOCHA","Inclusion Criteria:\n\n1. Undergoing primary ACL reconstruction\n2. Age between 25-50\n3. Concomitant meniscus injury\n\nExclusion Criteria:\n\n1. Undergoing revision procedures\n2. Multiple ligament injuries requiring multiple ligament reconstruction\u002Frepair\n3. Depressive symptoms and\u002For those who endorse suicidal ideation at the time of enrollment (PHQ-9 score \\>= 15)\n4. Found to not have a meniscus tear at the time of surgery","25 Years","50 Years",{"count":59,"type":20},30,[61],"EARLY_PHASE1","This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at greatest risk of rapid PTOA progression. Patients will randomly be assigned to receive oral montelukast (10 mg) versus placebo daily for 6 months after surgery.",[64,65,27],"ACL Injury","Meniscus Tear",[67,68],"knee ligament","osteoarthritis","2026-06-08",{"date":71,"type":40},"2026-06-10",{"date":73,"type":40},"2021-02-01",{"date":44,"type":20},{"name":76,"class":47},"Austin V Stone",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":15,"minAge":84,"maxAge":57,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":48},"100470939","phase-3-prp-in-aclr-to-prevent-ptoa-100470939","NCT05412381","PRP in ACLR to Prevent PTOA","Platelet Rich Plasma (PRP) Treatment of the Anterior Cruciate Ligament Injured Knee to Decrease the Risk of Post-traumatic Osteoarthritis (PTOA): a Randomized Double-blind Controlled Trial","Inclusion Criteria:\n\n* Acute ACL injury within 6 weeks of presentation\n* Age 14-50\n* Male or female\n* Meniscus injury that can be treated with meniscectomy or repair (the lack of meniscus injury will not exclude patients)\n\nExclusion Criteria:\n\n* Prior ACL reconstruction\n* Prior cartilage repair procedure\n* Prior meniscus surgery within 12 months\n* Prior steroid, hyaluronic acid, or PRP injection within 6 months\n* Other ligament injury requiring repair\n* Any cartilage lesion requiring repair\n* Any cartilage lesion greater than grade 2 (partial thickness injury)\n* History of inflammatory arthritis or joint sepsis\n* Non English speakers","14 Years",{"count":86,"type":20},56,[88],"PHASE3","The purpose of our study is to examine the effect of platelet-rich-plasma (PRP) injection on the short-term resolution of post-injury inflammation (biomarkers) and improvement in joint function in patients with acute ACL injury. This RCT has been powered based on the questionnaire KOOS Jr. but it is considered a 'pilot study' in terms of the lab analysis proposed.",[26,27,91],"PRP",[93,94,95,96],"platelet-rich plasma","regenerative medicine","anterior cruciate ligament reconstruction","post-traumatic osteoarthritis","2026-02-11",{"date":99,"type":40},"2026-02-13",{"date":101,"type":40},"2022-06-27",{"date":103,"type":20},"2026-12-31",{"name":105,"class":47},"Hospital for Special Surgery, New York",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":15,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":137},"100485642","exactech-shoulder-post-market-clinical-follow-up-study-100485642","NCT05603728","Exactech Shoulder Post Market Clinical Follow-up Study","An Open Label, Multi-Center, Retrospective and Prospective Evaluation of Shoulder Arthroplasty Clinical and Radiographic Outcomes","Inclusion Criteria:\n\n* Patient is indicated for shoulder arthroplasty (or has previously undergone shoulder arthroplasty)\n* Patient is skeletelly mature\n* Patient is expected to survive at least 2 years beyond surgery\n* Patient is willing to participate by complying with pre- and postoperative visit requirements\n* Patient is willing and able to read and sign a study informed consent form\n\nExclusion Criteria:\n\n* Osteomyelitis of the proximal humerus or scapula; if a systemic infection or a secondary remote infection is suspected or confirmed, implantation should be delayed until infection is resolved\n* Inadequate or malformed bone that precludes adequate support or fixation of the prosthesis\n* Medial humeral bone loss resulting in compromised humeral stem fixation\n* Proximal humeral bone loss extending distal to the surgical neck where there is compromised humeral stem fixation\n* Neuromuscular disorders that do not allow control of the joint\n* Significant injury to the brachial plexus\n* Non-functional deltoid muscles\n* Patient's age, weight, or activity level would cause the surgeon to expect early failure of the system\n* The patient is unwilling or unable to comply with the post-operative care instructions\n* Alcohol, drug, or other subtance abuse\n* Any disease state that could adversaly affect the function or longevity of the implant\n* Patient is pregnant\n* Patient is a prisoner\n* Patient is contraindicated for the surgery\n* Revision cases in which a stemmed humeral component was used (Stemless Shoulder System)\n* Metal allergy or sensitivity to the implants materials (Stemless Shoulder System)\n* Acute fracture of the proximal humerus and displacement of the tuberosities, displaced three or four part fractures of the proximal humerus (hemi-arthroplasty), or acture fracture of the proximal humerus with failure of the glenohumeral joint (total anatomic shoulder arthroplasty) (Stemless Shoulder System)\n* Acute fracture of the proximal humerus in combination with degenerative diseases of the glenohumeral joint and a grossly deficient, irreparable rotator cuff resulting in superior migration of the humeral head (reverse total shoulder arthroplasty) (Stemless Shoulder System)","21 Years",{"count":115,"type":20},20000,"OBSERVATIONAL","The objective of this study is to collect and evaluate long-term clinical and radiographic outcomes data in order to better understand the safety and performance of the shoulder arthroplasty over time. This study will follow subjects long-term for a minimum of 10-years, without an early-term restriction on the amount of time they will be followed.",[119,120,121,122,123,27,124,125,126],"Osteo Arthritis Shoulders","Osteonecrosis","Rotator Cuff Tears","Rotator Cuff Tear Arthropathy","Ankylosing Spondylitis","Rheumatoid Arthritis","Fracture","Infections","2025-12-09",{"date":129,"type":40},"2025-12-15",{"date":131,"type":40},"2007-07-19",{"date":133,"type":20},"2031-12-31",{"name":135,"class":136},"Exactech","INDUSTRY",38,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},"100429667","vibration-and-post-traumatic-osteoarthritis-risk-following-acl-injury-100429667","NCT04875052","Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury","The Effects of Vibratory Stimuli on Joint Health and Post-traumatic Osteoarthritis Risk Following Anterior Cruciate Ligament Injury","Inclusion Criteria:\n\n* Age 16 to 35 years\n* Unilateral, primary ACLR with bone-patellar tendon-bone autograft\n\nExclusion Criteria:\n\n* History of prior ACL injury or revision ACLR\n* History of prior knee surgery\n* Requirement of multiple ligament surgery at time of ACLR\n* Concomitant injuries or surgical procedures at the time of ACLR that would delay early post-operative weight bearing based on surgeon recommendations (e.g. lower extremity fracture, intra-articular fracture, microfracture procedure)\n* Removal of more than 1\u002F3 of the medial or lateral meniscus at the time of ACLR\n* Articular cartilage damage greater than 3A on the International Cartilage Repair Society Criteria at the time of ACLR\n* History of musculoskeletal injury to either leg in the 3 months prior to participation other than primary ACL injury\n* Prior diagnosis of radiographic OA in any joint of the lower extremity\n* History of neurological disorder (e.g. stroke, multiple sclerosis, etc.)\n* Contraindications for MRI (e.g. extreme claustrophobia, cardiac pacemaker, cochlear implant, metal foreign bodies, aneurism clip, etc.)\n* Pregnant or planning to become pregnant",{"count":146,"type":20},114,[23],"The goal of this randomized clinical trial is to evaluate the effects of vibration on factors related to the risks of post-traumatic knee osteoarthritis and secondary anterior cruciate ligament (ACL) injury in individuals who have undergone anterior cruciate ligament reconstruction surgery (ACLR). The main objectives are to compare the effects of Standard rehabilitation vs. rehabilitation that includes whole body vibration (WBV) or local muscle vibration (LMV) on:\n\n* Quadriceps muscle function\n* Gait biomechanics linked to post-traumatic knee osteoarthritis development\n* Patient self-report outcomes\n* MRI indicators of knee joint health and muscle quality\n* Landing biomechanics linked to secondary ACL injury risk\n* Evidence-based return-to-physical-activity criteria\n\nParticipants will be assigned to 1 of 3 groups (standard rehabilitation, standard rehabilitation + WBV, or standard rehabilitation + LMV) and will complete assessments of quadriceps function, gait biomechanics, landing biomechanics, functional ability, patient-report outcomes, and MRI 1, 6, and 12 months after ACLR. Researchers will compare the groups to see if vibration embedded in ACLR rehabilitation improves joint health outcomes.",[150,26,27,151],"Osteoarthritis, Knee","Quadriceps Muscle Atrophy","2025-05-27",{"date":154,"type":40},"2025-05-31",{"date":156,"type":40},"2021-01-11",{"date":158,"type":20},"2026-08",{"name":46,"class":47},2,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":15,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100523482","phase-2-preventing-injured-knees-from-osteoarthritis-severity-outcomes-100523482","NCT06096259","Preventing Injured Knees From osteoArthritis: Severity Outcomes","Preventing Injured Knees From osteoArthritis: Severity Outcomes (PIKASO)","PIKASO","Inclusion Criteria:\n\n1. Age 25-45 or Age 18-24 with preoperative KOOS Pain \\\u003C80 (0-100, 100 best) recorded at least 14 days after the day of ACL injury\n2. Plan to undergo ACL reconstruction within 12 months of injury\n\nExclusion Criteria:\n\n1. Inflammatory arthritis\n2. Pregnancy and\u002For lactation, or plans to become pregnant in the next 12 months\n3. Known contraindication to metformin\n4. Current use of metformin or topiramate\n5. Diabetes mellitus or diabetic ketoacidosis\n6. Acute or chronic renal insufficiency\n7. History of prior ACL tear on the index knee, with or without reconstruction\n8. History of ACL tear on the contralateral knee within the past 12 months\n9. Applying for or receiving Workers' Compensation for their knee injury\n10. Joint space narrowing AND definite osteophyte(s) on weightbearing radiograph on index knee\n11. Tibial plateau fracture on index knee\n12. Concomitant avulsion fracture of index knee that will be treated surgically\n13. Concomitant posterior cruciate ligament, medial collateral ligament, or lateral collateral ligament injury on index knee requiring surgical repair\u002Freconstruction\n14. Contraindication to MRI\n15. Unable to speak and understand English\n16. Diagnosis of cognitive impairment or otherwise unable to provide informed consent\n17. Insufficient time for recruitment and drug titration: Surgery scheduled for \\\u003C14 days from the time of screening\n18. Date of injury more than 6-months ago, relative to date of screening\n19. Presence of a condition or abnormality that in the opinion of the surgeon investigator would compromise the safety of the patient or the quality of the data\n20. Plan for allograft at time of consent","18 Years","45 Years",{"count":172,"type":20},512,[174],"PHASE2","This study is being done to find out if metformin is effective at reducing pain by delaying the onset of post-traumatic osteoarthritis (PTOA) after anterior cruciate ligament (ACL) reconstruction. This research study will compare metformin to placebo. The placebo tablet looks exactly like metformin, but contains no metformin. Placebos are used in research studies to see if the results are due to the study drug or due to other reasons.\n\nMetformin is approved by the U.S. Food and Drug Administration (FDA) to treat type II diabetes. Notably, it also has anti-inflammatory effects, suggesting it could benefit people who have an ACL injury and are undergoing ACL reconstruction.",[150,27,177],"ACL Tear","2025-04-25",{"date":180,"type":40},"2025-04-29",{"date":182,"type":40},"2024-05-06",{"date":184,"type":20},"2029-12",{"name":186,"class":47},"Brigham and Women's Hospital",9,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":15,"minAge":169,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":187},"100456771","safety-and-performance-assessment-of-the-symbol-range-of-medical-devices-in-patients-underlying-total-hip-arthroplasty-100456771","NCT05227924","Safety and Performance Assessment of the SYMBOL Range of Medical Devices in Patients Underlying Total Hip Arthroplasty","Inclusion Criteria:\n\n* Patient age \\> 18 years at implantation.\n* Patient who will undergo, during the study's period of inclusion, a total hip arthroplasty (primary or revision) with at least one SYMBOL medical device (DEDIENNE Santé).\n* Patient informed of his\u002Fher participation and willing to participate in the study.\n* Patient able to read, write and understand French.\n\nExclusion Criteria:\n\n* Patient deprived of freedom, under guardianship\u002Fcuratorship or placed under judicial protection\n* Patient unable to follow study procedures.\n* Patient who has already been included in the study for a total hip arthroplasty (primary or revision) with at least one SYMBOL medical device.",{"count":195,"type":20},747,"The purpose of this post-market clinical follow up study is to assess the safety and effectiveness of the SYMBOL range of medical devices. The study will evaluate the outcome of Total Hip Arthroplasty using medical devices from SYMBOL range over a period of 10 years.",[198,27,199,200,201,202],"Degenerative Hip Joint Disease","Hip Arthritis","Femoral Neck Fractures","Avascular Necrosis of the Femoral Head","Failure of Prosthetic Joint Implant","2024-08-26",{"date":205,"type":40},"2024-08-27",{"date":207,"type":40},"2021-09-21",{"date":209,"type":20},"2034-09",{"name":211,"class":136},"Dedienne Sante S.A.S.",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":15,"minAge":169,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":21,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":226,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":4},"100365080","freedom-total-knee-system-for-treatment-of-osteoarthritis-rheumatoid-arthritis-or-post-traumatic-arthritis-100365080","NCT04033588","Freedom® Total Knee System for Treatment of Osteoarthritis, Rheumatoid Arthritis or Post-traumatic Arthritis","A Prospective, Multi-centre, Non-comparative, Post-market Clinical Follow-up Study to Evaluate the Survivorship, Safety and Performance of the Freedom® Total Knee System in United Kingdom.","Freedom®450","Inclusion Criteria:\n\n* Male and female subjects aged between 18 years and 75 years.\n* Subjects who require unilateral knee prosthesis and have been evaluated as appropriate candidates for a total knee replacement by the investigator.\n* Subjects suffering from severe knee joint pain and loss of mobility due to rheumatoid arthritis, osteoarthritis or post-traumatic osteoarthritis.\n* Subjects, who in the opinion of the investigator are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow ups.\n* Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.\n\nExclusion Criteria:\n\n* Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.\n* Subjects who are known drug or alcohol abuse or with psychological disorders that could affect follow-up care or treatment outcomes.\n* Subject with a known sensitivity to device materials.\n* Subjects with other significant disabling problems from the muscular-skeletal system other than in the knees (i.e muscular dystrophy, polio, neuropathic joints).\n* Subjects with a BMI of 40 or above.\n* Subjects with a current or active history of malignancy, active or suspected infection, Paget's disease, renal osteodystrophy, immunologically suppressed or have any other significant medical illness judged by investigator to exclude from study.\n* Subject with neuromuscular or neurosensory deficiency that may limit ability of the patient to evaluate the safety and efficacy of the device.\n* Female subjects who are pregnant or lactating.\n* Subjects who have previously undergone total or unicondylar knee replacement, high tibial osteotomy, ligament reconstruction, open reduction internal fixation (ORIF) or with previous fracture in the ipsilateral knee joint.","75 Years",{"count":222,"type":20},450,[23],"A prospective, multi-centre, non-comparative, post-market clinical follow-up study to evaluate the survivorship, safety and performance of the Freedom® Total Knee System in the treatment of approximately 450 subjects who in the surgeon's opinion require a primary total knee replacement due to severe knee joint pain and loss of mobility due to osteoarthritis, rheumatoid arthritis or post-traumatic arthritis at upto 15 centers in the United Kingdom (UK). The primary objective of this study is to obtain implant survivorship and clinical outcomes data for commercially available Freedom® Total Knee System used in total knee replacement. Subjects must meet all the study inclusion \u002F exclusion criteria before enrolment in the study. Subjects will be requested to attend out-patients clinic for clinical follow-up (CFU) or approached for telephonic follow-up (TFU) post-operatively as mentioned below.\n\nClinical \\& Telephonic Follow-up details:\n\n* 6-8 weeks ± 1week (Clinical follow-up)\n* 1 year ± 1 month (Clinical follow-up)\n* 3 years ± 6 months (Clinical follow-up)\n* 5 years ± 6 month (Clinical follow-up (optional) \u002F Telephonic follow-up)\n* 10 years± 6 month (Clinical follow-up (optional) \u002F Telephonic follow-up)",[28,124,27],"NOT_YET_RECRUITING","2020-10-01",{"date":229,"type":40},"2020-10-05",{"date":231,"type":20},"2021-01-01",{"date":233,"type":20},"2032-09-01",{"name":235,"class":136},"Meril Life Sciences Pvt. Ltd."]